March 22, 2019 Upcoming events – Roche aims to change autism and Ocular awaits pivotal results Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
November 29, 2018 Go or no go? Roche, Jazz and Camarus await crucial regulatory readouts The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.
